NYHA Class IV Approval: In August 2024, scPharmaceuticals announced that the U.S. Food and Drug Administration (FDA) granted approval for FUROSCIX, expanding the indication to include New York Heart ...
This concept encompasses the entire data lifecycle, from creation and modification ... DSI provides regulatory, technical, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback